OakChart

Alumis Inc

ALMSHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 12:04 PM ET

6.63+0.23 (3.63%)
2026-11-11 18:04 CET
Market cap
854.37 USD m
Revenue, TTM
7.40 USD m
Net income, TTM
-438.96 USD m
Free cash flow, TTM
-351.80 USD m
EPS diluted, TTM
-3.81
P/E
-
Compare

Price

ALMS against its 20, 50 and 200-day averages
2050200beatmiss
10.0020.0030.0014.2M28.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALMSclose 6.6320-day 6.5350-day 7.44200-day 20.656.6352w high52w low

78.8% under the 52-week high of 31.35 on 8 Jul 2026. 52-week low 4.60 on 14 Nov 2025. Last 15 sessions, 26.0% high to low

Profile

ALMS
52-week range, 8% of the way up
4.6031.35

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

IndexRUT
Employees224
IPOJun 28, 2024
Beta-0.21
ATR, 14d0.49
Rel volume0.29
Short float11.57%
Insider own28.54%
Inst own68.59%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap885.35M
Enterprise Value419.49M
Income-438.96M
Sales7.40M
Book/sh3.52
Cash/sh3.76
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees224
IPOJun 28, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S119.64
P/B1.88
P/C1.76
P/FCF-
EV/EBITDA-
EV/Sales56.69
Quick Ratio6.74
Current Ratio6.74
Debt/Eq0.08
LT Debt/Eq0.07
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.81
EPS next Y-2.82
EPS next Q-0.75
EPS this Y-14.16%
EPS next Y13.66%
EPS next 5Y10.01%
EPS past 3/5Y-9.85% -
Sales past 3/5Y- -
EPS Y/Y TTM15.36%
Sales Y/Y TTM-63.11%
EPS Q/Q-243.88%
Sales Q/Q-37.66%
EarningsAug 13 AMC
EPS/Sales Surpr.-44.85% -54.49%

Ownership

Insider Own28.54%
Insider Trans2.33%
Inst Own68.59%
Inst Trans3.25%
ROA-74.94%
ROE-93.65%
ROIC-90.74%
Gross Margin52.31%
Oper. Margin-5479.55%
Profit Margin-5933.45%
SMA201.51%
SMA50-10.90%
SMA200-67.89%
Trades-

Technical

Shs Outstand124.45M
Shs Float95.39M
Short Float11.57%
Short Ratio4.02
Short Interest11.03M
52W High31.35 -78.84%
52W Low4.60 44.18%
Volatility8.02% 7.06%
ATR (14)0.49
RSI (14)43.78
Beta-0.21
Rel Volume0.29
Avg Volume2.74M
Volume334,522

Performance

Perf Week1.25%
Perf Month1.10%
Perf Quarter-72.83%
Perf Half Y-73.32%
Perf YTD-32.05%
Perf Year25.13%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.30
Target Price31.12
Prev Close6.40
Price6.63
Change %3.63%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Sep 03, 2026DowngradeGGuggenheimBuy → Neutral
Sep 02, 2026UpgradeHH.C. WainwrightNeutral → Buy$15+126.2%
May 15, 2026DowngradeHH.C. WainwrightBuy → Neutral$25+277.0%
Mar 11, 2026InitiatedRRaymond JamesStrong Buy$46+593.6%
Feb 25, 2026InitiatedSStifelBuy$44+563.4%
Jan 21, 2026InitiatedCChardan Capital MarketsBuy$37+457.9%
Jul 25, 2025InitiatedWWells FargoOverweight$17+156.3%
Jun 10, 2025ResumedGGuggenheimBuy$18+171.4%
Jan 30, 2025InitiatedOOppenheimerOutperform$32+382.5%
Oct 31, 2024InitiatedRRobert W. BairdOutperform$25+277.0%

Peers

Mkt cap
TickerCompanyMkt cap
PTGXProtagonist Therapeutics Inc8.71B
ORKAOruka Therapeutics Inc7.30B
MLTXMoonLake Immunotherapeutics1.11B
VRDNViridian Therapeutics Inc3.55B
TAKTakeda Pharmaceutical Co ADR66.23B
BMYBristol-Myers Squibb Co126.34B
ARQTArcutis Biotherapeutics Inc3.58B
ACRSAclaris Therapeutics Inc681.24M
KYMRKymera Therapeutics Inc11.53B
SYRESpyre Therapeutics Inc9.97B

Insider trading

latest 14 of 47
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Schroer John R.Chief Financial OfficerNov 02 '26Sale6.527945,17723,924Nov 04 04:46 PM
Pangali SanamChief Legal OfficerNov 02 '26Sale6.523322,1659,415Nov 04 04:41 PM
Hardiman Roy C.Chief Business & Strategy OfcrNov 02 '26Sale6.526524,251207,094Nov 04 04:37 PM
Goldstein David MChief Scientific OfficerNov 02 '26Sale6.526294,10130,341Nov 04 04:35 PM
Drappa JornChief Medical OfficerNov 02 '26Sale6.525933,86656,299Nov 04 04:22 PM
Bradley Mark ChristopherChief Development OfficerNov 02 '26Sale6.526234,06247,910Nov 04 04:19 PM
AKKARAJU SRINIVASDirectorSep 08 '26Buy10.63546,5815,808,5714,937,026Sep 09 09:39 PM
AKKARAJU SRINIVASDirectorSep 04 '26Buy11.17440,1404,917,6844,711,801Sep 09 09:39 PM
AKKARAJU SRINIVASDirectorSep 08 '26Sale10.5596,1311,014,0282,025,493Sep 09 09:39 PM
Schroer John R.Chief Financial OfficerAug 03 '26Sale26.373,28286,54624,718Aug 05 06:50 PM
Pangali SanamChief Legal OfficerAug 03 '26Sale26.371,36435,9699,747Aug 05 06:46 PM
Hardiman Roy C.Chief Business & Strategy OfcrAug 03 '26Sale26.372,69270,988207,746Aug 05 06:44 PM
Goldstein David MChief Scientific OfficerAug 03 '26Sale26.372,59668,45730,970Aug 05 06:40 PM
Drappa JornChief Medical OfficerAug 03 '26Sale26.372,44764,52756,892Aug 05 06:36 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 176
  • Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact (Clinical Trials Arena)
  • Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures (GlobeNewswire)
  • Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
  • ALMS Stock Clocks Worst Day After 57% Drop What Drove The Selloff? (Stocktwits) -56.58% +9.29%
  • A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It (Barrons.com)
  • Loading…
  • Alumis Phase 2b lupus trial misses primary and secondary endpoints (InvestorsHub)
  • Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
  • Alumis TYK2 drug fails in key lupus study (BioPharma Dive)
  • Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements (GlobeNewswire)
  • Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies (GlobeNewswire) -7.85%
  • Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive) -7.15%
  • Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements (GlobeNewswire)
  • Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-1.111-0.767-1.1101.663.6510
2026Q12026-05-14-0.743-0.743-0.7441.742.0611
2025Q42026-03-19-0.909-0.923-0.8881.932.3611
2025Q32025-11-13-1.060-0.933-1.0642.073.178
2025Q22025-08-130.8000.7730.7742.672.694
2025Q12025-05-14-1.820-1.486-1.82317.391.675
2024Q42025-03-19-1.736-1.390-1.7420.000.006
2024Q32024-11-13-1.730-1.778-1.7120.000.006
2024Q22024-08-13-8.537-1.460-1.0390.000.002
2024Q12024-05-29-4.500--0.9620.00--
2026Q3---0.746--1.9010
2026Q4---0.731--1.9010
2027Q1---0.702--0.756
2027Q2---0.697--0.756
2027Q3---0.652--4.606
2027Q4---0.625--11.786

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-10.380-6.655-5.4080.000.00
2025FY-2.869-2.864-2.86024.0524.26
2026FY--3.265--6.40
2027FY--2.819--27.04
2028FY--2.084--156.35
2029FY--0.723--414.95
2030FY-1.742--884.16

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-288001.900.005.00
2026Q3S2026-08-148211.900.005.00
2026Q3S2026-08-128111.700.005.00
2026Q3S2026-07-307001.570.005.00
2026Q3S2026-06-038002.000.005.00
2026Q3S2026-05-158012.000.005.00
2026Q3S2026-03-208012.000.005.00
2026Q3S2026-03-188002.130.005.00
2026Q3S2026-03-097002.000.005.00
2026Q3S2026-02-236002.330.005.00
2026Q3S2026-02-055001.800.005.00
2026Q3S2026-01-264002.250.005.00
2026Q3S2026-01-204102.250.005.00
2026Q3S2025-11-143101.330.004.00

Estimate history

EPS, annual-2.159-2.99-5.408-2.862-3.8093
Period2022202320242025TTM
EPS, quarterly-1.039-1.712-1.742-1.8230.774-1.064-0.888-0.744-1.114
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00024.057.4
Period2022202320242025TTM
Sales, quarterly00017.3892.6662.0661.9291.7411.662
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual51.84551.84554.407104.707128.505
Period2022202320242025MRQ
Shares, quarterly54.40354.40754.40754.407104.042104.359104.707127.23128.505
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue7.4024.050.000.000.00
Cost of Goods Sold Incl. D&A3.533.503.151.280.25
Gross Profit3.8720.55-3.15-1.28-0.25
Selling, General and Administrative Excl. Other409.25447.76297.60156.89113.60
Research and Development338.57377.10262.40136.39101.05
Other Operating Expense0.000.000.000.000.00
Operating Income-405.38-427.20-300.75-158.17-113.85
Interest Expense0.000.000.000.000.00
Unusual Expense53.6226.605.410.120.00
Net Income Before Taxes-440.71-251.89-294.23-154.99-111.93
Income Taxes-1.76-8.560.000.000.00
Consolidated Net Income-438.96-243.32-294.23-154.99-111.93
Net Income From Continuing Operations-438.96-243.32-294.23-154.99-111.93
Net Income-438.96-243.32-294.23-154.99-111.93
EPS (Recurring)-3.14-2.64-5.34-2.99-2.16
EPS (Basic, Before Extraordinaries)-3.81-2.86-5.41-2.99-2.16
EPS (Diluted)-3.81-2.86-5.41-2.99-2.16
EBITDA-401.85-423.71-297.60-156.89-113.60
Non-Operating Income (Expense)18.29201.9211.933.301.92
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense36.8634.3819.468.625.96
Price To Sales Ratio485.7034.51---
Gross Margin52.3185.46---
Operating Margin-5,479.55-1,776.32---
Net Margin-5,933.45-1,011.75---
Shares Outstanding128.51104.7154.4151.8451.84
Market Capitalization854.37854.37427.64409.14-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.661.741.932.072.6717.390.000.00
Cost of Goods Sold Incl. D&A0.870.870.870.920.870.840.820.81
Gross Profit0.790.871.061.151.8016.55-0.82-0.81
Selling, General and Administrative Excl. Other107.8299.2885.61116.54135.24110.3797.8097.58
Research and Development84.4680.6776.5296.92107.8995.7886.3887.01
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-107.03-98.41-84.55-115.39-133.44-93.83-98.62-98.40
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense41.820.0011.90-0.107.107.700.000.00
Net Income Before Taxes-143.98-93.05-92.93-110.7550.76-98.96-94.76-93.12
Income Taxes-1.760.000.000.00-8.560.000.000.00
Consolidated Net Income-142.22-93.05-92.93-110.7559.32-98.96-94.76-93.12
Net Income From Continuing Operations-142.22-93.05-92.93-110.7559.32-98.96-94.76-93.12
Net Income-142.22-93.05-92.93-110.7559.32-98.96-94.76-93.12
EPS (Recurring)-0.88-0.74-0.81-1.060.84-1.72-1.74-1.71
EPS (Basic, Before Extraordinaries)-1.11-0.74-0.89-1.060.78-1.82-1.74-1.71
EPS (Diluted)-1.11-0.74-0.89-1.060.77-1.82-1.74-1.71
EBITDA-106.16-97.54-83.68-114.48-132.57-92.98-97.80-97.58
Non-Operating Income (Expense)4.885.363.514.54191.302.563.865.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.289.758.117.7314.727.006.367.31
Price To Sales Ratio485.70327.8842.4918.7811.4619.17--
Gross Margin47.4149.9755.0555.6667.3795.15--
Operating Margin-6,439.89-5,652.44-4,382.84-5,585.29-5,005.21-539.58--
Net Margin-8,557.22-5,344.80-4,817.57-5,360.702,225.09-569.11--
Shares Outstanding128.51127.23104.71104.36104.0454.4154.4154.41
Market Capitalization854.372,802.191,018.88415.22309.57334.06427.64504.29

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments308.58288.2649.0693.07
Short Term Receivables2.081.810.610.50
Inventories0.000.000.000.00
Other Current Assets7.5716.113.688.98
Total Current Assets318.23306.1953.36102.56
Net Property, Plant & Equipment35.1633.6935.224.47
Total Investments and Advances1.301.111.021.14
Intangible Assets50.96--0.00
Deferred Tax Assets4.20---
Other Assets6.290.010.010.00
Total Assets416.14340.9989.61108.17
Short Term Debt Incl. Current Port. of LT Debt4.671.561.721.31
Accounts Payable10.110.000.000.00
Other Current Liabilities58.5449.3519.1512.04
Total Current Liabilities73.3250.9120.8713.35
Long Term Debt32.2429.1630.860.47
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities6.34---
Other Liabilities2.940.811.774.12
Total Liabilities114.8480.8953.5017.94
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00375.37285.47
Common Equity301.30260.10-339.26-195.24
Total Shareholders Equity301.30260.1036.1190.23
Accumulated Minority Interest0.000.000.000.00
Total Equity301.30260.1036.1190.23
Total Liabilities & Stockholders Equity416.14340.9989.61108.17
Book Value Per Share2.884.78-6.54-3.77
Tangible Book Value Per Share2.394.78-6.54-3.77
Full-Time Employees224168--
Price to Book Ratio1.821.231.17-
Return on Assets-64.28-136.66-156.73-
Return on Equity-86.68-198.66-245.36-
Return on Invested Capital-72.95-101.72-231.44-123.41
Quick Ratio4.346.012.567.68
Current Ratio4.346.012.567.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-438.96-243.32-294.23-154.99-111.93
Depreciation3.533.503.151.280.25
Other Funds (Non Cash)82.29-147.4521.2411.685.87
Funds from Operations-361.70-395.84-269.84-142.03-105.81
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital10.3026.3214.7612.06-1.92
Cash from Operating Activities-351.40-369.52-255.08-129.97-107.72
Capital Expenditures-0.40-0.65-1.73-4.50-2.41
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-97.54238.79-112.0664.97-66.34
Purchase of Investments-652.69-209.17-240.06-11.28-209.07
Sale Or Maturity of Investments555.15447.95128.0076.25142.73
Other Uses0.000.000.000.000.00
Other Sources0.0049.740.000.000.00
Cash from Investing Activities-97.94287.88-113.7960.47-68.75
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock360.932.07492.3790.17101.63
Repurchase of Common Pref Stock0.00-0.02-0.01-0.060.00
Sale of Common Pref Stock360.932.08492.3790.23101.63
Proceedsfrom Stock Options326.201.59491.7889.7899.89
Issuance or Reduction of Debt, Net0.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.480.00
Other Financing Activities Uses0.000.000.00-0.480.00
Cash from Financing Activities360.932.07492.3789.68101.63
Net Change in Cash-88.41-79.58123.5020.18-74.85
Free Cash Flow-351.80-370.18-256.81-134.47-110.13
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit--8.560.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments502.29523.03308.58377.72486.69208.75
Short Term Receivables3.862.732.083.647.861.29
Inventories0.000.000.000.000.000.00
Other Current Assets7.936.657.5711.9323.0115.49
Total Current Assets514.08532.41318.23393.29517.56225.53
Net Property, Plant & Equipment34.1233.4935.1636.5738.5534.56
Total Investments and Advances1.3947.911.301.371.381.16
Intangible Assets9.1350.9650.9650.9650.96-
Deferred Tax Assets--4.20---
Other Assets1.896.836.295.822.480.04
Total Assets560.62671.59416.14488.01610.92261.30
Short Term Debt Incl. Current Port. of LT Debt4.824.444.674.414.062.54
Accounts Payable12.8011.5910.114.5514.980.00
Other Current Liabilities58.6154.8858.5456.4566.5457.91
Total Current Liabilities76.2370.9073.3265.4285.5860.45
Long Term Debt31.6131.2232.2433.3834.7229.34
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.382.146.342.142.14-
Other Liabilities0.240.302.942.303.173.20
Total Liabilities108.46104.57114.84103.24125.6092.98
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity452.16567.02301.30384.77485.33168.31
Total Shareholders Equity452.16567.02301.30384.77485.33168.31
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity452.16567.02301.30384.77485.33168.31
Total Liabilities & Stockholders Equity560.62671.59416.14488.01610.92261.30
Book Value Per Share3.524.462.883.694.663.09
Tangible Book Value Per Share3.454.062.393.204.173.09
Full-Time Employees--224--184
Price to Book Ratio1.827.662.650.860.971.28
Return on Assets-74.94-50.90-64.28-54.44-51.94-156.54
Return on Equity-93.65-64.57-86.68-66.88-66.35-247.05
Return on Invested Capital-29.40-15.55-27.86-26.4911.41-50.07
Quick Ratio6.747.514.346.016.053.73
Current Ratio6.747.514.346.016.053.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-142.22-93.05-92.93-110.7559.32-98.96
Depreciation0.870.870.870.920.870.84
Other Funds (Non Cash)54.5411.407.229.13-170.086.28
Funds from Operations-86.81-80.78-93.40-100.71-109.89-91.84
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.31-6.3021.49-10.203.5411.49
Cash from Operating Activities-81.50-87.08-71.91-110.91-106.35-80.36
Capital Expenditures-0.24-0.160.000.00-0.62-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments68.93-285.5295.0124.0480.2739.47
Purchase of Investments-39.67-428.38-47.52-137.110.00-24.54
Sale Or Maturity of Investments108.60142.86142.53161.1580.2764.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.0049.740.00
Cash from Investing Activities68.69-285.6995.0124.04129.4039.43
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock12.63346.991.320.000.750.00
Repurchase of Common Pref Stock0.000.000.000.00-0.020.00
Sale of Common Pref Stock12.63346.991.320.000.770.00
Proceedsfrom Stock Options1.57323.800.830.000.770.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities12.63346.991.320.000.750.00
Net Change in Cash-0.18-25.7824.42-86.8723.80-40.93
Free Cash Flow-81.74-87.25-71.91-110.91-106.97-80.39

Revenue breakdown

Collaboration2025: 6.66M
License2025: 17.39M
United States2025: 24.05M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.57%11.0M95.4M2.64M
2026-10-1511.62%11.1M95.4M2.47M
2026-09-3010.79%10.3M95.4M2.40M
2026-09-156.60%6.3M95.4M2.23M
2026-08-315.86%5.6M96.3M1.29M
2026-08-146.08%5.9M96.3M1.31M
2026-07-316.67%5.8M86.4M1.30M
2026-07-157.83%6.8M86.4M1.36M
2026-06-3016.53%14.3M86.5M1.29M
2026-06-1514.64%12.7M86.4M1.32M
2026-05-2913.23%11.1M83.7M1.28M
2026-05-1513.56%11.4M83.8M1.36M
2026-04-3013.65%11.3M82.7M1.43M
2026-04-1514.76%12.2M82.7M1.55M
2026-03-3115.06%11.2M74.6M3.12M
2026-03-1312.59%9.0M71.2M2.91M
2026-02-2711.17%8.0M71.2M2.92M
2026-02-1312.72%9.1M71.2M2.92M
2026-01-3012.02%8.7M72.1M2.88M
2026-01-1512.02%8.7M72.1M2.60M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.003.207.605.200.0001.000.000.987-0.0140.000
call2.002.106.800.000.0000.000.000.960-0.0300.001
call3.002.405.800.0017.5460.000.000.939-0.0290.001
call4.000.203.400.006.0450.000.000.911-0.0270.002
call5.000.204.802.157.6199.000.000.867-0.0240.002
call6.000.251.100.701.8763100.000.678-0.0470.004
call7.000.200.550.251.8051,3263.000.514-0.0540.004
call8.000.000.350.051.9024771.000.317-0.0390.004
call9.000.000.150.051.7722580.000.171-0.0260.003
call10.000.000.300.052.15636.000.000.149-0.0290.002
call11.000.004.800.002.4780.000.000.135-0.0310.002
call12.000.000.050.002.1870.000.000.058-0.0140.001
call13.000.000.050.002.3950.000.000.054-0.0140.001
call14.000.004.800.002.5860.000.000.051-0.0160.001
call15.000.002.300.002.7660.000.000.049-0.0160.001
call16.000.004.800.002.9320.000.000.046-0.0170.001
put1.000.000.050.006.8070.000.00-0.013-0.0120.000
put2.000.002.600.005.9660.000.00-0.040-0.0300.001
put3.000.002.600.004.1370.000.00-0.061-0.0290.001
put4.000.004.800.002.8770.000.00-0.089-0.0270.002
put5.000.000.150.131.6584000.00-0.147-0.0200.002
put6.000.100.550.252.2425370.00-0.322-0.0460.004
put7.000.051.850.744.0812660.00-0.486-0.0530.004
put8.000.902.151.603.1301310.00-0.683-0.0380.004
put9.001.854.803.407.62227.000.00-0.829-0.0250.003
put10.003.004.703.405.6410.002.00-0.851-0.0280.002
put11.002.106.800.008.7390.000.00-0.865-0.0300.002
put12.003.207.800.009.0880.000.00-0.942-0.0130.001
put13.004.208.800.009.3980.000.00-0.946-0.0140.001
put14.005.209.700.009.4290.000.00-0.949-0.0140.001
put15.007.4010.700.009.6830.000.00-0.951-0.0140.001
put16.007.2011.700.009.9150.000.00-0.954-0.0150.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-018-KCurrent report2026-09-01SEC
2026-08-17SCHEDULE 13DSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-06SCHEDULE 13GSEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-27SCHEDULE 13GSEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-028-KCurrent report2026-06-30SEC
2026-07-02SCHEDULE 13D/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110023.62K6
2026-100000
2026-0910.73M21.01M1
2026-0800394.31K6
2026-0700140.00K1
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-0131.00M400
2025-124.52M500
2025-1115.43M1900

Institutional holders

Manager% owned
AyurMaya Capital Management Company, LP11.88%
BlackRock, Inc.6.45%
Deep Track Capital, LP4.98%
Samsara BioCapital, LLC4.98%
Foresite Capital Management V, LLC4.63%
PRICE T ROWE ASSOCIATES INC /MD/4.08%
venBio Partners LLC3.55%
Foresite Capital Management VI LLC3.33%
VANGUARD CAPITAL MANAGEMENT LLC3.31%
Nextech Invest Ltd.2.78%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.46%
iShares Russell 2000 ETF1.58%
T. Rowe Price New Horizons Fund, Inc.1.07%
Fidelity Small Cap Growth Fund0.87%
Fidelity Stock Selector Small Cap Fund0.87%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.85%
VANGUARD EXTENDED MARKET INDEX FUND0.77%
Fidelity Advisor Biotechnology Fund0.74%
Select Health Care Portfolio0.73%
Fidelity Small Cap Index Fund0.68%

OakChart. ALMS. Cached 15 minutes.